Viramune XR - (400 mg; Tablet, Extended Release)

Generic Name	Nevirapine	**Innovator**	Boehringer Ingelheim
Dosage	400 mg; Tablet, Extended Release	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	Less Than 5
Other ANDA developers	None	**Tentative Approvals**	Less Than 5
Final Approvals	More Than 5	**Generic Launches**	None
Indication	Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 6 to less than 18 years of age		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.